PT  - JOURNAL ARTICLE
AU  - M Pérez Abánades
AU  - C Martínez Nieto
AU  - E Alañón Plaza
AU  - A Aranguren Oyarzábal
AU  - E Deben Tiscar
AU  - E Ramírez Herráiz
AU  - T Gallego Aranda
AU  - A Ibañez Zurriaga
AU  - A Morell Baladrón
TI  - DGI-055 Protease Inhibitors: New Drugs For Treatment of Chronic Hepatis C
AID  - 10.1136/ejhpharm-2013-000276.321
DP  - 2013 Mar 01
TA  - European Journal of Hospital Pharmacy: Science and Practice
PG  - A115--A116
VI  - 20
IP  - Suppl 1
4099  - http://ejhp.bmj.com/content/20/Suppl_1/A115.2.short
4100  - http://ejhp.bmj.com/content/20/Suppl_1/A115.2.full
SO  - Eur J Hosp Pharm2013 Mar 01; 20
AB  - Background The protease inhibitors boceprevir and telaprevir are indicated for treatment of chronic hepatitis C (CHC) genotype 1 in combination with peginterferon-alfa and ribavirin. These drugs increase efficacy and adverse effects. Purpose To study the effectiveness and safety of boceprevir and telaprevir for treatment of CHC. Materials and Methods Retrospective observational study including all patients who started treatment with telaprevir or boceprevir for treatment of CHC from January to September 2012. Collected data: age, sex, type of patient (treatment-naive, recurrent or non-responder), liver fibrosis, HIV coinfection, viral loads at weeks 0, 4, 8, 12, 24 to evaluate efficacy and adverse effects and supportive treatment to evaluate safety. View this table:Abstract DGI-055 Table 1 Baseline characteristics View this table:Abstract DGI-055 Table 2 Efficacy and safety Results We included 51 patients, 35 (70%) men and 15 (30%) women, with a mean age of 51 years. 5 patients were co-infected with HIV (off-label use). Conclusions Most patients had grade 3–4 liver fibrosis. Most patients were recurrent or non-responders to previous treatment. Telaprevir was the most used protease inhibitor. Patients using telaprevir got negative viral loads before patients using boceprevir. A high percentage of patients using boceprevir required the dose of peginterferon-alfa to be reduced and treatment with G-CSF due to neutropenia. No conflict of interest.